...
首页> 外文期刊>Medicine. >Early postoperative tumor marker responses provide a robust prognostic indicator for N3 stage gastric cancer
【24h】

Early postoperative tumor marker responses provide a robust prognostic indicator for N3 stage gastric cancer

机译:术后早期肿瘤标志物反应为N3期胃癌提供了有力的预后指标

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The clinical significance of tumor markers after radical gastrectomy has not been well characterized. The purpose of this study is to evaluate the prognostic value of early postoperative tumor marker normalization in N3 stage gastric cancer (GC) patients. A total of 259 N3 stage GC patients with preoperatively elevated carcinoembryonic antigen (CEA, >5 ng/mL) or carbohydrate antigen 19-9 (CA19-9, >37 U/mL) levels underwent radical gastrectomy were analyzed retrospectively. Early postoperative tumor marker response was considered as a normalization of CEA or CA19-9 levels 4 weeks after surgery. The disease-free survival (DFS) and overall survival (OS) were analyzed. N3 stage GC patients were divided into N3a (n = 157) and N3b (n = 102) groups according to the 8th TNM stage system. Early tumor marker response was identified in 96 of 157 N3a patients (61.15%) and 57 of 102 N3b patients (55.88%). In N3 stage GC patients with a tumor marker response, significant increase was observed in both DFS (25.2 months vs 12.5 months, P < .001) and OS (32.5 months vs 18.5 months, P < .001) compared with those without tumor marker response. N3b patients with a tumor marker response showed more favorable DFS (19.2 months vs 13.6 months, P = .019) and OS (25.8 months vs 19.0 months, P = .013) compared with N3a patients lacking a tumor marker response. Multivariate analysis revealed that early tumor marker response was an independent factor for DFS and OS in N3 stage GC, as well as for depth of invasion and metastatic lymph node rate ( P < .05). Early postoperative CEA or CA19-9 normalization serves as a strong prognostic indicator in N3 stage GC. Both N3a and N3b patients with increased early postoperative tumor marker levels showed poor outcomes.
机译:根治性胃切除术后肿瘤标志物的临床意义尚未得到很好的表征。这项研究的目的是评估N3期胃癌(GC)患者术后早期肿瘤标记物正常化的预后价值。回顾性分析了259例N3期GC患者的术前癌胚抗原(CEA,> 5 ng / mL)或碳水化合物抗原19-9(CA19-9,> 37 U / mL)水平升高,行根治性胃切除术。术后4周,早期术后肿瘤标志物反应被认为是CEA或CA19-9水平的正常化。分析了无病生存期(DFS)和总体生存期(OS)。根据第8个TNM分期系统,将N3期GC患者分为N3a(n = 157)和N3b(n = 102)组。在157名N3a患者中的96名(61.15%)和102名N3b患者中的57名(55.88%)中发现了早期肿瘤标志物反应。在N3期具有肿瘤标志物反应的GC患者中,与无肿瘤标志物的患者相比,DFS(25.2个月对12.5个月,12.5个月,P <.001)和OS(32.5个月对18.5个月,P <.001)均显着增加。响应。与缺乏肿瘤标志物反应的N3a患者相比,具有肿瘤标志物反应的N3b患者显示出更佳的DFS(19.2个月对13.6个月,P = .019)和OS(25.8个月对19.0个月,P = .013)。多变量分析显示,早期肿瘤标志物反应是N3期GC中DFS和OS以及浸润深度和转移性淋巴结发生率的独立因素(P <.05)。术后早期CEA或CA19-9正常化可作为N3期GC的有力预后指标。术后早期肿瘤标志物水平升高的N3a和N3b患者均显示不良预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号